Avery Dennison Corporation (NYSE:AVY), a leader in biotech innovation, has been experiencing a varied mix of market reactions recently. The company posted a
quarterly dividend of $0.88, which is seen as a
reward to its shareholders. Despite hits at
52-week lows, financial analysts and investors are not concerned, highlighting the strength of the firm's fundamentals.
Its
Q4 earnings beat estimates, leading to certain research groups like JPMorgan and Raymond James upgrading its stock rating, anticipating an upward price correction. Nevertheless, Avery Dennison's
2025 EPS outlook fell short of expectations, causing a dip in its share price.
Investment advisors and asset management firms such as KBC Group and Manning & Napier have increased their stakes, indicating a promising long-term view, while some other advisors and asset managers have trimmed their hold.
Clover health analyst turned bullish on Avery Dennison, while others reduced their price target. Q4 sales were in line with estimates, yet the firm missed the quarterly earnings expectation by $0.01 EPS.
Avery Dennison Stocks AVY News Analytics from Fri, 22 Jun 2018 00:40:02 GMT to Sat, 01 Feb 2025 22:10:23 GMT -
Rating 0
- Innovation 0
- Information 5
- Rumor -5
